Wednesday, July 8, 2026

pharma · Breast Cancer · NSCLC (Advanced Non-small Cell Lung Cancer) · ALXO

ALX ONCOLOGY HOLDINGS

ALX ONCOLOGY HOLDINGS is a pharma organization headquartered in San Antonio, USA. It trades on NYSE under ticker ALXO. Primary therapeutic focus areas include Breast Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), A

4545 Horizon Hill Blvd, San Antonio, Texas 78229-2263, US HQ
2015 Founded
2 Employees
Public company Type
ALXO · NYSE Ticker
Company details
Status
Public
HQ
4545 Horizon Hill Blvd, San Antonio, Texas 78229-2263, US
Founded
2015
Employees
2
Programs
13
Drugs
16
Patents
0
Clinical program

Evorpacept (ALX148)

Phase 2 · small molecule · Breast Cancer, Metastatic

Evorpacept (ALX148) for Breast Cancer, Metastatic is a Phase 2 program (small_molecule) at ALX ONCOLOGY HOLDINGS INC with 1 ClinicalTrials.gov record(s).

← All ALX ONCOLOGY HOLDINGS INC projects Phase 2 small molecule active

Internal code AT148009

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
ALX ONCOLOGY HOLDINGS INC
Phase
Phase 2
Modality
small_molecule
Indication
Breast Cancer, Metastatic
Status
active
Trials
1

Clinical trials